|Day Low/High||25.53 / 26.79|
|52 Wk Low/High||4.50 / 37.25|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Expands portfolio of partner-funded programs with potential for milestone and royalty payments
X213 shown to be safe and effective, demonstrating complete suppression of lactation in study participants
Unmet medical needs in parathyroid hormone-related hypercalcemia contribute to potential partnering value of overall portfolio
Oral and Poster Presentations to Highlight Preclinical and Clinical Program Advances for Hypoglycemia and Hypercalcemia
Company extinguishes Hercules term loan; repayment further reduces operating expenses and strengthens XOMA's balance sheet, reflecting its new business strategy
Company outlines new strategic imperatives and value drivers
Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom; Company initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.